Published • loading... • Updated
Artrya Limited Posts Wider Loss Despite US Commercialisation Drive
Summary by sharecafe.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Artrya Limited Posts Wider Loss Despite US Commercialisation Drive
Artrya Limited (ASX: AYA), a commercial-stage medical technology company leveraging advanced imaging and artificial intelligence to transform the assessment of coronary artery disease, has reported a widened loss for the financial year ended 30 June 2026. The company posted a loss from ordinary activities after tax attributable to owners of $25,183,000, an increase of 53.5% from the $16,406,000 loss recorded in the previous corresponding period.…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
![[Reporter's Notebook] ‘National Team’ NPU, Time to Stand on Its Own](/_next/image?url=https%3A%2F%2Fgrnd.b-cdn.net%2Finterests%2Fd2ce81aa9d39b3491d893cc3c21fa0c6f895781d.jpg&w=1440&q=75)
